TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Predicting the pathological subtype of lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion MRI structural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI resting state functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diaphragm motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression, Anxiety and Stress Scale (DASS) - 21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: World Health Organization Quality of Life Instruments (WHOQOL-BREF) - psychological health component
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Perceived pain and fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Perceived Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Response: Hematological Improvement - Erythroid (HI-E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percent minutes of cerebral hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freiburger Monosyllable Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma ALT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Forced Expiratory Volume in 1 Sec (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: One-time success rate of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in immune status measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in lymphocyte activity and cytokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in viral load in response to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cerebral Aβ plaque status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Elapsed Time From the Date of Underlying Condition Diagnosis to the Date of SBS-IF Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Elapsed Time From the Date of SBS-IF Diagnosis to the Date of Intestinal Transplant Procedure Indication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Elapsed Time From the Date of Intestinal Transplant Indication to the Date of Intestinal Transplant Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vaginal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress level as measured by DASS-21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor-free survival rate at 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival (OS) rate at 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Corneal Changes Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Post operative neurologic deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Comparison of transcriptomic profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretome and single-cell phosphoproteome comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunophenotyping of intrahepatic mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Single Fiber Electromyography (sfEMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Effectiveness of patient information tools
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: State/ Trait Anxiety Inventory-STAI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological Well-Being Scale (PIOS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse Events (AE) after CT1190B infusion
Endpoint domain: Adverse events/effects
Primary endpoint: breast milk DHA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast milk Vitamin A concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast milk Vitamin E concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast milk Vitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast milk Zinc concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: breast milk Calcium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: satisfaction in terms of pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction regarding the attack duration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction with regard to the speed of action
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction regarding the migraine-induced cognitive impact
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: satisfaction with regard to the tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: satisfaction about the relief of other symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Genetic Testing Uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Event Related Rumination Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Post Traumatic Growth Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rates of urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion rate from MRD-positive to MRD-negative CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Geometric mean concentration of anti-gE antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Gross motor function measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute HRV variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic tooth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration [Cmax] of cis-CTB and AVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of cis-CTB and AVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of cis-CTB and AVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Brain Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Power per beat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular pulmonary artery coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical outcome of patients with DLBCL or HGBCL
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Diagnosis of Anorexia Nervosa or Bulimia Nervosa follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain regarding the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hemorrhagic clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative change in apnea-hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of infants with B cell levels (CD19+ cells) below the lower limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Attention Task Performance Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention Task Performance Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hemoglobin (Hb) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of morphine administrated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to vaccination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of pediatric patients requiring daily general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to first occurrence of composite outcome (50% decline in eGFR, ESRD, CV Death, Renal Death)
Endpoint domain: Mortality/survival
Primary endpoint: Need for additional treatment within the 3rd month
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of complication within 6 months after intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Incontinence Quality of Life Scale (I-QOL) scores at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CD4+ T-cell number change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: axSPA global activity score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: axSPA global activity score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: axSPA global activity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence and type of pathological variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Silness and Löe plaque index (PI-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Gingival index (GI-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Halitosis/ VSCs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Biomarkers in exhaled breath condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory function measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of awakening agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the Personalized Neoantigen Peptide Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of the Personalized Neoantigen Peptide Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lumber lordotic angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of Adverse Device Effects (ADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in esophageal acid exposure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Awareness for cancer risk factors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge of the European Code Against Cancer recommendations
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cancer prevention beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Information retrieval
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Japanese Cancer Intelligence Quotient
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma Concentration of lisinopril, valsartan, amlodipin, indapamide, metoprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: facial action unit detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: event-related potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in skin wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tolerance of Albendazole 400mg/day
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacity of Albendazole 400mg/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of distinct nodular lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BCG recoverable from bronchial sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic change of [18F]-IMA601 regional total volume of distribution (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Questionnaires (including Epworth Sleepiness Scale, Pittsburgh Sleep Questionnaire Index, Snore Outcomes Survey etc.)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vitamin D induced genes' expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soleus muscle activation pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean percentage of Fasting Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in frequency of vasomotor symptoms (VMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual frailty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sepsis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of AKI KDIGO stage 2 or 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Death within 72 hours after end of cardiac surgery
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline Beck Depression Inventory II at 2 Months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Beck Depression Inventory II at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Verified abstinence at Month 6
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Annualized bleed rate (ABR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual treated bleed rate (ATBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung injury identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hierarchical composite of Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Ipsilateral Stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Number of undiagnosed and misdiagnosed cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Umbilical Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications requiring an intervention
Endpoint domain: Adverse events/effects
Primary endpoint: World Health Organization Quality of Life Scale-BREF score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum oxygen consumption (VO₂ max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported xerostomia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MiniAsthma Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of Hallux Valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in COVID-19 IgG Antibody (Relative Light Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-whitening sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Average hospital length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: rehospitalisation for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: MI size as a % of LV mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intramyocardial bleeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimally clinically significant improvement in depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiovascular fitness test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flexibility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking effects on pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Smoking effects on the fetus
Endpoint domain: Life impact
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Interruption in Index Anticoagulant Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Treatment Interruption
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Completely Discontinued Index Anticoagulant Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Range of Motion (Posterior pelvic tilt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of Motion (AKE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of Motion (SLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 1-year disease stabilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month disease stabilization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propulsion speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of foot propulsion gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived difficulty with foot propulsion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major Cardiovascular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time spent assessing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of action recognition using clinical data from scratch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of skills assessment using clinical data from scratch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K fold accuracies for action recognition and skills assessment for the complete retraining of the pretrained network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistence of SBD111 and SBD121 microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lifespan of the intravenous (IV) cannulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to negativisation via PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: absence of pain and/or swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence or change of periapical radiolucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of daily fruit and vegetable portions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blastulation Rate per Mature Oocyte (M2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in degree of parasympathetic denervation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of moderate-to-severe systemic bleeding within 3 days post-randomization
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of premalignant conditions and malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of uterine leiomyoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline intravaginal ejaculatory latency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dermatological assessment of skin signs on the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Genitourinary Pain Index (GUPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year all-caused mortality
Endpoint domain: Mortality/survival
Primary endpoint: 3-year Gastric-Cancer Specific Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Clinical Assessment of Cutaneous Tolerance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes